These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 670902)

  • 21. [Action of a decarboxylase inhibitor on endogenous plasmatic DOPA, in man].
    Geissbuhler F; Constantinidis J; Gaillard JM; des Combes NJ; Tissot R
    Biomedicine; 1974 Jul; 21(7):297-8. PubMed ID: 4433662
    [No Abstract]   [Full Text] [Related]  

  • 22. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 23. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase.
    Schultz E
    Biomed Chromatogr; 1990 Nov; 4(6):242-4. PubMed ID: 2289048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A reliable and simple method for simultaneous determination of DOPA and 3-O-methyldopa in plasma and brain.
    Fahn S; Prasad AL; Delesie R
    Anal Biochem; 1972 Apr; 46(2):557-75. PubMed ID: 4337048
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dopegit in the combined treatment of vitiligo patients].
    Mirakhmedov UM; Rakhmatov BR; Rakhmatov AB; Raimdzhanova MR; Kamzolova KP
    Vestn Dermatol Venerol; 1985 Jun; (6):56-8. PubMed ID: 4036307
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 30. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 31. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.
    Curzon G; Kantamaneni BD; Trigwell J
    Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man.
    Schwartz DE; Brandt R
    Arzneimittelforschung; 1978; 28(2):302-7. PubMed ID: 580398
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug-induced changes of extracerebral dopa metabolism in man.
    Tissot R; Bartholini G; Pletscher A
    Arch Neurol; 1969 Feb; 20(2):187-90. PubMed ID: 5767016
    [No Abstract]   [Full Text] [Related]  

  • 34. Assay and stability of alpha-methyldopa in man using high-performance liquid chromatography with electrochemical detection.
    Ong H; Sved S; Beaudoin N
    J Chromatogr; 1982 May; 229(2):433-8. PubMed ID: 7096478
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of methyldopa on creatinine estimation.
    Maddocks J; Hann S; Hopkins M; Coles GA
    Lancet; 1973 Jan; 1(7795):157. PubMed ID: 4118507
    [No Abstract]   [Full Text] [Related]  

  • 36. [Endogenous 3-O-methyldopa in man: normal level and effect of an inhibitor of aromatic amino-acid decarboxylase (Benserazid) (author's transl)].
    Geissbühler F; Raffin Y; Combépine C; Streiff U; Hovaguimian T
    J Clin Chem Clin Biochem; 1978 Jun; 16(6):355-8. PubMed ID: 670902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 39. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.